Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sirukumab + methotrexate
- Development stage
- Phase 3
- Lead developer
- Johnson & Johnson
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Subcutaneous, Oral
01
Overview
A combination therapy consisting of sirukumab, a human monoclonal antibody that selectively binds to and neutralizes interleukin-6 (IL-6), and methotrexate, a small molecule antimetabolite and immunosuppressant. Sirukumab is designed to block the pro-inflammatory effects of IL-6, a cytokine implicated in the pathogenesis of rheumatoid arthritis (RA). Methotrexate acts by inhibiting folate-dependent enzymes and modulating immune responses through multiple mechanisms, including adenosine accumulation and suppression of T and B cell function. This combination has been studied for the treatment of active rheumatoid arthritis, particularly in patients unresponsive to methotrexate or TNF inhibitors[1][3][4][5][7].
02
Targets
ADA (Adenosine deaminase)ATIC (Aminoimidazole carboxamide ribonucleotide transformylase)DHFR (Dihydrofolate reductase)IL-6 (Interleukin 6)IL-1R (Interleukin-1 receptor type 1 (IL-1R1))
Beyond the preview
Go deeper on sirukumab + methotrexate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sirukumab + methotrexate.